Cancer Immunology: New Advances in Personalized Therapies

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 25 May 2025 | Viewed by 112

Special Issue Editor


E-Mail Website
Guest Editor
Department of Translational Science and Medicine, College of Community Health Sciences, The University of Alabama, Tuscaloosa, AL, USA
Interests: cancer drug discovery; immuno-oncology; targeted drug delivery

Special Issue Information

Dear Colleagues,

A compromised immune system is a hallmark of cancer. Dysfunctional immune cells in the tumor microenvironment (TME) contribute to tumor growth, metastasis and resistance. Treatments aimed at restoring the immune system not only minimize toxicities and enhance patients’ quality of life but also pave the way for personalized therapy.

Even though the concept of using the host immune system to destroy cancer dates back to the nineteenth century, immunotherapy techniques have gained prominence in the oncology field in recent years. This is demonstrated by the approval of therapies involving CAR T-cells, bispecific T-cell engager antibodies, immune checkpoint inhibitors and cancer vaccines. Despite their encouraging clinical outcomes in a variety of cancer types, only a subset of patients benefit from these treatments. Recent advances in multi-omic technologies, biomarker identification, and neoantigen discovery have all helped to improve our understanding of the tumor-immune network within the TME. However, there are challenges that must be addressed in order to provide safe, effective and predictable personalized treatment for cancer.

This Special Issue aims to highlight recent developments in immune cell targeting, immunoprevention, immunotherapy and immune microenvironment modulation strategies for personalized cancer therapy.

In this Special Issue, original research articles, systematic reviews and other papers are welcome. Research areas may include the following: cell-based therapies, antibody-based therapies, immune-modulating agents, checkpoint inhibitor therapies, small-molecule agonists/antagonists/inhibitors, immune cell engagers, clinical trials, targeted drug delivery and novel immunotherapeutic combinations.

I look forward to receiving your contributions to this Special Issue.

Dr. John Victor Napoleon
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • personalized therapy
  • immune system modulation
  • drugs and pharmaceutics
  • checkpoint inhibitor therapy
  • cancer immunotherapy
  • targeted drug delivery
  • tumor microenvironment
  • treatment resistance
  • combination therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop